Nationwide cohort study reveals the features and outcomes of fulminant myocarditis

heart
Credit: Unsplash/CC0 Public Domain

Myocarditis is an inflammatory disease of the myocardium often caused by viral infections or autoimmune disorders. Fulminant myocarditis (FM) is a rare and severe presentation of myocarditis characterized by hemodynamically unstable conditions requiring inotropes and/or mechanical circulatory support. The natural history of FM and its clinical features are incompletely understood because there is a lack of generalizable evidence.

A team of researchers at the Nara Medical University and National Cerebral and Cardiovascular Center performed a nationwide cohort study of patients with histologically proven FM, in 235 cardiovascular hospitals across Japan. They revealed that the 90 days mortality was 29%, and some specific clinical findings such as older age, non-sinus rhythm on admission, left ventricular ejection fraction <40%, and ventricular arrhythmia on the first day, and severe histological damage of myocardium were all associated with worse prognosis.

"A comprehensive assessment of both clinical and pathologic findings may help the prediction of outcome in patients with FM. Our results showed that about half of the patients with clinically diagnosed FM did not undergo endomyocardial biopsy, and increasing the implementation of biopsy may improve the management of FM," said Dr. Koshiro Kanaoka.

Next steps for this research are to clarify the effective treatment and the immunological mechanism of inflammation in patients with FM.

The research has been published in Circulation.

More information: Koshiro Kanaoka et al, Features and Outcomes of Histologically-Proven Myocarditis with Fulminant Presentation, Circulation (2022). DOI: 10.1161/CIRCULATIONAHA.121.058869

Journal information: Circulation
Provided by National Cerebral and Cardiovascular Center
Citation: Nationwide cohort study reveals the features and outcomes of fulminant myocarditis (2022, September 30) retrieved 10 May 2024 from https://medicalxpress.com/news/2022-09-nationwide-cohort-reveals-features-outcomes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Patients with heart failure benefit from dapagliflozin regardless of ejection fraction

56 shares

Feedback to editors